Daraxonrasib Pancreatic Cancer Trial

What Is Daraxonrasib for Pancreatic Cancer?

Daraxonrasib is a multi-selective RAS(ON) inhibitor being studied for metastatic pancreatic ductal adenocarcinoma. RAS genes, especially KRAS, are among the most important molecular drivers in pancreatic cancer, and Dana-Farber Cancer Institute notes that more than 90 percent of patients with pancreatic cancer have cancer-driving KRAS mutations.

The drug is designed to inhibit active RAS proteins rather than attacking cancer cells through traditional chemotherapy mechanisms. That matters because metastatic pancreatic cancer has historically had limited second-line treatment options, and many patients receive additional chemotherapy after first-line treatment stops working.

How Much Did Daraxonrasib Improve Survival?

The RASolute 302 trial enrolled 500 patients with metastatic pancreatic cancer across North America, Europe and Asia. Participants had already received one line of chemotherapy for metastatic disease and were randomized to receive either daraxonrasib or investigator-selected second-line chemotherapy.

According to results reported at the American Society of Clinical Oncology annual meeting and published in the New England Journal of Medicine, daraxonrasib improved both overall survival and progression-free survival. Median progression-free survival was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy, while objective response rates were also higher in the daraxonrasib group.

Who Might Benefit if Daraxonrasib Is Approved?

The trial population reflects a common and difficult clinical scenario: metastatic pancreatic cancer that has progressed after an initial chemotherapy regimen. If regulators approve daraxonrasib, oncologists would need to integrate it alongside molecular testing, performance status assessment, prior treatment history and patient goals.

Daraxonrasib is not yet an FDA-approved pancreatic cancer treatment. Dana-Farber reported that the FDA allowed an expanded access program to begin, and further studies are evaluating whether the drug could be used earlier in treatment, including with or without chemotherapy in the first-line setting.